Repurposing a Histone Deacetylase 2 (HDAC-2) Specific Inhibitor as a Potential Treatment for Alzheimer's Disease (AD)

被引：0
|
作者：
Ibia, I. E. [1 ]
Mobbs, C. V. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Reston, VA USA
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
B127
引用
收藏
页码：S132 / S133
页数：2
相关论文
共 50 条
  • [31] In Silico Investigation of Traditional Chinese Medicine Compounds to Inhibit Human Histone Deacetylase 2 for Patients with Alzheimer's Disease
    Hung, Tzu-Chieh
    Lee, Wen-Yuan
    Chen, Kuen-Bao
    Chan, Yueh-Chiu
    Lee, Cheng-Chun
    Chen, Calvin Yu-Chian
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [32] Therapeutic potential of histone deacetylase inhibitor for treatment of Niemann-Pick type C1 disease
    Nina H Pipalia
    Frederick R Maxfield
    Molecular Cytogenetics, 7 (Suppl 1)
  • [33] Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8
    Stoddard, Shana V.
    May, Xavier A.
    Rivas, Fatima
    Dodson, Kyra
    Vijayan, Sajith
    Adhika, Swetha
    Parker, Kordarius
    Watkins, Davita L.
    MOLECULAR INFORMATICS, 2019, 38 (03)
  • [34] Histone deacetylase-2: A potential regulator and therapeutic target in liver disease (Review)
    Liu, Ya-Ru
    Wang, Jie-Quan
    Huang, Zhao-Gang
    Chen, Ruo-Nan
    Cao, Xi
    Zhu, Dong-Chun
    Yu, Hai-Xia
    Wang, Xiu-Rong
    Zhou, Hai-Yun
    Xia, Quan
    Li, Jun
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2021, 48 (01)
  • [35] THERAPEUTIC POTENTIAL OF SELECTIVE INHIBITION OF HISTONE DEACETYLASE 6 (HDAC6) IN DIFFERENT FORMS OF CMT2
    Benoy, V
    d'Ydewalle, C.
    Van den Berghe, P.
    Van Demme, P.
    Kozikowski, A. P.
    Robberecht, W.
    Van den Bosch, L.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2015, 20 (02) : 103 - 104
  • [36] Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease
    Bradner, James E.
    Mak, Raymond
    Tanguturi, Shyam K.
    Mazitschek, Ralph
    Haggarty, Stephen J.
    Ross, Kenneth
    Chang, Cindy Y.
    Bosco, Jocelyn
    West, Nathan
    Morse, Elizabeth
    Lin, Katherine
    Shen, John Paul
    Kwiatkowski, Nicholas P.
    Gheldof, Nele
    Dekker, Job
    DeAngelo, Daniel J.
    Carr, Steven A.
    Schreiber, Stuart L.
    Golub, Todd R.
    Ebert, Benjamin L.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (28) : 12617 - 12622
  • [37] Biophenols of mints: Antioxidant, acetylcholinesterase, butyrylcholinesterase and histone deacetylase inhibition activities targeting Alzheimer's disease treatment
    Hanafy, Doaa M.
    Prenzler, Paul D.
    Burrows, Geoffrey E.
    Ryan, Danielle
    Nielsen, Sharon
    El Sawi, Salma A.
    El Alfy, Taha S.
    Abdelrahman, Enas H.
    Obied, Hassan K.
    JOURNAL OF FUNCTIONAL FOODS, 2017, 33 : 345 - 362
  • [38] Lacosamide reduces HDAC levels in the brain and improves memory: Potential for treatment of Alzheimer's disease
    Bang, Shraddha R.
    Ambavade, Shirishkumar D.
    Jagdale, Priti G.
    Adkar, Prafulla P.
    Waghmare, Arun B.
    Ambavade, Prashant D.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2015, 134 : 65 - 69
  • [39] The antitumor effects of OSU-HDAC42, a novel histone deacetylase inhibitor, in HER-2-positive breast cancer
    Weng, S.
    Wu, E.
    Kulp, S. K.
    Wang, D.
    Chen, C.
    Yee, L. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] From Antipsychotic to Neuroprotective: Computational Repurposing of Fluspirilene as a Potential PDE5 Inhibitor for Alzheimer's Disease
    Bhattacharya, Kunal
    Bhattacharjee, Atanu
    Chakraborty, Manodeep
    Das, Dibyajyoti
    Paudel, Keshav Raj
    JOURNAL OF COMPUTATIONAL CHEMISTRY, 2025, 46 (02)
12345